Does higher transforming growth factor beta-1 indicate immune dysregulation and contribute to fatigue?

Transforming growth factor beta-1 (TGF-β1) is a multifunctional pleiotropic cytokine that serves as a central orchestrator of the immune system. While it is essential for maintaining immune tolerance, pathological elevations are frequently observed in states of chronic inflammation, immune dysregulation, and aging-related fatigue syndromes.

TGF-β1 as a central immune regulator

TGF-β1 is definitively classified as an immune signaling cytokine that modulates the activity of nearly all immune cell types. It utilizes complex signaling pathways to maintain homeostasis:

• Signaling pathways: It binds to specific receptors (TβRI and TβRII), activating canonical Smad-dependent pathways and non-canonical cascades, including MAPK and PI3K/AKT.
• Cellular effects: In T cells, TGF-β1 is critical for suppressing excessive proliferation and promoting the differentiation of regulatory T cells (Tregs). In macrophages, it promotes an M2-like immunosuppressive phenotype, which is vital for the resolution of inflammation but can contribute to immune evasion if persistently activated.

Clinical significance of elevated TGF-β1

Higher levels of TGF-β1 are robustly supported as biomarkers for ongoing immune dysregulation and tissue remodeling.

• Immune pathogenesis: In conditions like systemic lupus erythematosus (SLE) and multiple sclerosis (MS), serum levels are significantly elevated during active disease phases, reflecting T-cell/B-cell imbalances and neutrophil recruitment.
• Fibrotic signaling: Sustained elevation is a primary driver of fibrosis in the heart, kidneys, and lungs—a process of particular concern in aging populations. Pathological ranges vary by assay; however, levels exceeding 25,000 pg/ml have been associated with significant disease activity in inflammatory conditions like sarcoidosis.

Mechanistic links to fatigue and systemic effects

The link between TGF-β1 and fatigue-related systemic effects is considered plausible, supported by mechanistic reasoning and specific clinical observations, though human data remains inconsistent.

• Neuroinflammation: In animal models, increased TGF-β1 activation in brain astrocytes is specifically linked to fatigue-like behaviors.
• Mitochondrial and aging factors: In older adults, TGF-β1 is a master regulator of aging-associated inflammation (inflammaging). It has been correlated with mitochondrial DNA depletion and cellular senescence, both of which are systemic drivers of physical frailty and fatigue.
• CFS/ME observations: Some case-control studies in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) have found significantly higher TGF-β levels at rest (median 43.9 ng/ml compared to 18.9 ng/ml in healthy controls), although other studies have failed to replicate these exact correlations.

Bottom line

TGF-β1 is a fundamental immune signaling cytokine, and its elevation is a well-established marker of immune dysregulation and chronic inflammatory signaling. While it is plausibly linked to fatigue through mechanisms involving neuroinflammation and mitochondrial stress—relevant in the context of aging and chronic illness—direct clinical correlation with fatigue severity scores requires further large-scale validation to be considered definitive.